The COVID-19 therapeutic landscape rapidly evolved throughout the course of the SARS-
CoV-2 pandemic. However, the ingenuity of our community quickly coalesced to identify …

The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines …

The harmful COVID-19 pandemic caused by the SARS-CoV-2 coronavirus imposes the
scientific community to develop or find conventional curative drugs, protective vaccines, or …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Monoclonal antibodies (MAbs) targeting the Spike glycoprotein of SARS-CoV-2 is a key
strategy to prevent severe COVID-19. Here, the efficacy of two monoclonal antibody …

Since being declared a global pandemic by the World Health Organization WHO),
Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory …

Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …

Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability
to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory …

Neutralizing antibodies for the treatment of COVID-19 Page 1 1134 comment Neutralizing
antibodies for the treatment of COVID-19 More clinical trial data are needed to determine …

Hunt for improved monoclonals against coronavirus gathers pace - Document - Gale OneFile:
Health and Medicine Use this link to get back to this page. Copy Skip to Content Library Menu …